A revolutionary technology

Dr. Aznarez and Professor Krainer’s early work led to the development of our proprietary TANGO platform, which is designed to allow us to deliver disease-modifying therapies to a wide-range of relevant tissues in a highly precise, durable and controlled manner.  While the TANGO mechanisms are novel, Stoke is able to leverage antisense chemistry that has been clinically validated for the central nervous system (CNS), which we believe minimizes the safety and biodistribution risks for Stoke’s CNS programs, including Dravet syndrome and other genetic epilepsies.